UB Paderborn / Katalog / Suche / in CDI

PCN98 Health Outcome Gains and Costs Offset Associated With Everolimus for the Treatment of Hormone-Receptor–Positive (HR+) HER2-Negative (HER2–) Advanced Breast Cancer (ABC)

Value in health, 2012-11, Vol.15 (7), p.A427-A427

2012

Link zum Volltext

Verfügbarkeit prüfen

6572 POSTER Effect of Everolimus + Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours – Analysis From RADIANT-2

European journal of cancer (1990), 2011, Vol.47, p.S463-S463

2011

Link zum Volltext

Verfügbarkeit prüfen

6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)

European journal of cancer (1990), 2011, Vol.47, p.S461-S461

2011

Link zum Volltext

Verfügbarkeit prüfen

PCN59 Patterns of Clinical Management and Resource Utilization for Postmenopausal Hormone Receptor–Positive HER2-Negative (HR+ HER2–) Advanced Breast Cancer (ABC) in Europe

Value in health, 2012-11, Vol.15 (7), p.A419-A419

2012

Link zum Volltext

Verfügbarkeit prüfen

6564 POSTER Correlation of PFS With Early Response of Chromogranin A and 5-hydroxyindoleacetic Acid Levels in Pts With Advanced Neuroendocrine Tumours: Phase III RADIANT-2 Study Results

European journal of cancer (1990), 2011, Vol.47, p.S460-S460

2011

Link zum Volltext

Verfügbarkeit prüfen

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

Chest, 2013-04, Vol.143 (4), p.955-962

2013

Link zum Volltext

Verfügbarkeit prüfen

Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients

Antimicrobial Agents and Chemotherapy, 1993-09, Vol.37 (9), p.1869-1872

1993

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-10-03: Comparative efficacy of everolimus in combination with exemestane and chemotherapy for advanced breast cancer in terms of progression-free survival

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-10-03

2013

Link zum Volltext

Verfügbarkeit prüfen

Mitoxantrone: an active, new antitumor agent with an improved therapeutic index

Cancer treatment reviews, 1987-12, Vol.14 (3), p.297-303

Saletan, S.

1987

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Clinical Management and Resource Utilization for Postmenopausal Hormone-Receptor–Positive HER2-Negative (HR+ HER2–) Advanced Breast Cancer (ABC) in Europe

Annals of oncology, 2012-09, Vol.23, p.ix122

2012

Link zum Volltext

Verfügbarkeit prüfen

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI : Journal of the National Cancer Institute, 2023-09, Vol.115 (9), p.1001-1010

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-16-17

2013

Link zum Volltext

Verfügbarkeit prüfen

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4075-4075

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4103-4103

2011

Link zum Volltext

Verfügbarkeit prüfen

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients (pts) with advanced neuroendocrine tumors: Multivariate analysis of progression-free survival from the RADIANT-2 trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e21084-e21084

2011

Link zum Volltext

Verfügbarkeit prüfen

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Multivariate analysis of progression-free survival from the RADIANT-3 trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e21091-e21091

2011

Link zum Volltext

Verfügbarkeit prüfen

Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.10527-10527

2011

Link zum Volltext

Verfügbarkeit prüfen

Familial essential thrombocythemia

The American journal of medicine, 1986-03, Vol.80 (3), p.497-502

1986

Link zum Volltext

Verfügbarkeit prüfen

Expression of Ia-antigens on normal and chronic myeloid leukemic human granulocyte-macrophage colony-forming cells (CFU-GM) is associated with the regulation of cell proliferation by prostaglandin E

Blood, 1982-02, Vol.59 (2), p.284-292

1982

Link zum Volltext

Verfügbarkeit prüfen

Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex

Annals of oncology, 1991-09, Vol.2 (8), p.589-596

1991

Link zum Volltext

Verfügbarkeit prüfen

Restoration of Responsiveness of Chronic Myeloid Leukemia Granulocyte-Macrophage Colony-Forming Cells to Growth Regulation In Vitro Following Preincubation With Prostaglandin E

Blood, 1983-07, Vol.62 (1), p.158-165

1983

Link zum Volltext

Verfügbarkeit prüfen

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)

Leukemia, 1990-03, Vol.4 (3), p.177-183

1990

Link zum Volltext

Verfügbarkeit prüfen

A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1

Cancer biotherapy, 1993, Vol.8 (1), p.3-16

1993

Link zum Volltext

Verfügbarkeit prüfen

Original article: Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex

Annals of oncology, 1991-10, Vol.2 (8), p.589-596

1991

Link zum Volltext

Verfügbarkeit prüfen

Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities

Journal of liposome research, 1993, Vol.3 (3), p.451-471

1993

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

PCN98 Health Outcome Gains and Costs Offset Associated With Everolimus for the Treatment of Hormone-Receptor–Positive (HR+) HER2-Negative (HER2–) Advanced Breast Cancer (ABC)

6572 POSTER Effect of Everolimus + Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours – Analysis From RADIANT-2

6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)

PCN59 Patterns of Clinical Management and Resource Utilization for Postmenopausal Hormone Receptor–Positive HER2-Negative (HR+ HER2–) Advanced Breast Cancer (ABC) in Europe

6564 POSTER Correlation of PFS With Early Response of Chromogranin A and 5-hydroxyindoleacetic Acid Levels in Pts With Advanced Neuroendocrine Tumours: Phase III RADIANT-2 Study Results

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients

Abstract P6-10-03: Comparative efficacy of everolimus in combination with exemestane and chemotherapy for advanced breast cancer in terms of progression-free survival

Mitoxantrone: an active, new antitumor agent with an improved therapeutic index

Patterns of Clinical Management and Resource Utilization for Postmenopausal Hormone-Receptor–Positive HER2-Negative (HR+ HER2–) Advanced Breast Cancer (ABC) in Europe

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2

Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients (pts) with advanced neuroendocrine tumors: Multivariate analysis of progression-free survival from the RADIANT-2 trial

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Multivariate analysis of progression-free survival from the RADIANT-3 trial

Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results

Familial essential thrombocythemia

Expression of Ia-antigens on normal and chronic myeloid leukemic human granulocyte-macrophage colony-forming cells (CFU-GM) is associated with the regulation of cell proliferation by prostaglandin E

Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex

Restoration of Responsiveness of Chronic Myeloid Leukemia Granulocyte-Macrophage Colony-Forming Cells to Growth Regulation In Vitro Following Preincubation With Prostaglandin E

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)

A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1

Original article: Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex

Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities

Suchergebnisse filtern